Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human B7-2 / CD86 Protein, Fc tag, 2x500 µg  

Recombinant human B7-2 / CD86 Protein, Fc tag, 2x500 µg

Recombinant Human B7-2 / CD86 (Leu 26 - Pro 247), expressed from human 293 cells (HEK293), Fc tag

Synonym
CD86, B7-2, B70, CD28LG2, LAB72, MGC34413

More details

CD6-H5257-1K

Availability: within 7 days

1 440,00 €

Background
Cluster of Differentiation 86 (CD86), also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily,[1] and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival.[2] Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.[3]

Source
Recombinant Human B7-2, Fc Tag (CD6-H5257) is expressed from human 293 cells (HEK293). It contains AA Leu 26 - Pro 247 (Accession # AAH40261).
Predicted N-terminus: Leu 26

Molecular Characterization
rhCD86-Fc, fused with Fc fragment of human IgG1 at the C-terminus and has a calculated MW of 51.5 kDa expressed. The predicted N-terminus is Leu26. Protein migrates as 80-95 kDa in reduced SDS-PAGE due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the rhCD86-Fc by the LAL method.

Purity
>96% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM tris, 100 mM glycine, pH7.0. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
Measured by its ability to induce IL2 secretion by Jurkat human acute T cell leukemia cells. The ED50 for this effect is typically 1.1 - 2.4 µg/ml in the presence of PHA.

References

(1) Chen C, et al., 1994, J. Immunol. 152 (10): 4929–36.
(2) Yadav, D. et al., 2007, J. Immunol. 178: 6236-6241.
(3) Steidl C, et al., 2010, N. Engl. J. Med. 362 (10): 875–85.

The following products could also be interesting for you: